EVALUATION OF EFFICACY OF TEST FORMULATIONS IN RAT MODEL OF L-ARGININE-INDUCED ACUTE PANCREATITIS

EVALUATION OF EFFICACY OF TEST FORMULATIONS IN RAT MODEL OF L-ARGININE-INDUCED ACUTE PANCREATITIS

1.0  TEST SYSTEM DETAILS:

Species                   : Rattus norvegicus (Rats)

Strain                     : Sprague Dawley or Wistar

Age                        : 6-7 weeks

Sex                        : Male

No. of animals        : 8/Group

Total animals         : 88

 

2.0  TEST ARTICLES DETAILS

HF1: Rheum emodi-based herbal formulation 

 

3.0  VEHICLE DETAILS

The test articles will be formulated by utilizing 0.5% methylcellulose as the vehicle.

4.0   ALLOCATION OF GROUPS:

 

Group No.	Group Description	Disease Induction procedure	Treatment administered	Dose Volume and Route
G1	Normal Control	Normal Saline administered by intraperitoneal route (i.p.), twice at 1-hour interval	0.5% MC, p.o., b.i.d.	5 ml/kg, p.o.
G2	Disease Control	L-Arginine-3.2 g/kg (dissolved in Normal Saline), i.p., twice at an interval of 1 hour	0.5% MC, p.o., b.i.d.
G3	Reference Control		Carvedilol-5 mg/kg, p.o., b.i.d.
G4	Treated with low dose of  HF1		HF1: 5-15 mg/kg, b.i.d.
G5	Treated with intermediate dose 1 of HF1		HF1: 15-50 mg/kg, b.i.d.
G6	Treated with intermediate dose 2 of HF1		HF1: 50-150 mg/kg,   b.i.d.
G7	Treated with high dose of HF1		HF1: 150-500 mg/kg,  b.i.d.

Abbreviations: MC: Methylcellulose, p.o.-per os. q.d.: quaque die; bid: bis in die.

5.0  METHOD:

·         Healthy animals will be selected for the study, randomized based on body weight, and will be assigned to 11 groups consisting of 8 animals each.

·         Animals of Group G1 will be designated as normal-control and administered 0.5% MC, p.o., b.i.d., two weeks prior to disease induction and will be continued till the end of the experiment.

·         Disease control animals (assigned to group G2) will receive 0.5% MC, p.o., b.i.d., two weeks prior to disease induction and will be continued till the end of the experiment.

·         Animals of group G3 will be treated with reference drug carvedilol at the dose of 5 mg/kg, p.o., b.i.d., two weeks prior to disease induction and will be continued till the end of the experiment.

·         Animals of group G4-G7 will be treated with HF1, at different incremental dose levels as outlined in Section 4.0 of Annexure-I, twice daily, two weeks prior to disease induction, and will be continued till the end of the experiment.

·     Normal control group (G1) will be administered two injections of Normal Saline by intraperitoneal route, whereas animals allocated to groups G2 – G7 will be administered two injections of 20% L-Arginine solution (3.2 g/kg, i.p.) dissolved in Normal Saline.

·         20% L-Arginine solution will be prepared in Normal Saline, its pH adjusted to 7.0 and filtered through syringe filter into a sterile tube in a properly sterilised environment.

·         Three days after administration of L-Arginine they will be sacrificed under overdose of thiopentone anaesthesia. After suitable anaesthesia but before the animal dies, blood will be collected from the retro-orbital plexus for the estimation of biochemical parameters. Immediately after the animal dies, pancreas will be weighed and one half will be fixed in 10% neutral buffered formalin for histopathology whereas the other half will be stored at -80°C for various biochemical and molecular evaluations.

 

6.0  PARAMETERS TO BE EVALUATED:

·         Body weight: Twice a week.

·         Pancreatic weight and its relative organ weight.

·         Serum biochemistry parameters: Lipase, Amylase, LDH, Total Proteins.

·         Cytokine estimation in serum: IL-10, IL-1β, TNF-α, IL-6, IL-22 (anti-inflammatory)

·      Oxidative stress parameters in the pancreas: Reduced and oxidized Glutathione, Malondialdehyde, Catalase, Total nitrate, Total anti-oxidant capacity (TAC).

·         Gene expression analysis by Real Time PCR: Pancreatitis associated protein (PAP), Nrf2, Sirt1, TNF-α, Caspase-3, iNOS, TGF-β1

·         Pancreatic amylase and Total protein estimation

·         Histopathological analysis of pancreas (Hematoxylin & Eosin-stained).

·         Immunofluorescence staining of the pancreatic tissue

 

7.0  REFERENCE(S):

1.        El Morsy, E. M. & Ahmed, M. A. E. Carvedilol attenuates L-arginine induced acute pancreatitis in rats through modulation of oxidative stress and inflammatory mediators. Chem. Biol. Interact. 327, 109181 (2020).

2.        Abdelzaher, W. Y. et al. Vinpocetine ameliorates L-arginine induced acute pancreatitis via Sirt1/Nrf2/TNF pathway and inhibition of oxidative stress, inflammation, and apoptosis. Biomed. Pharmacother. 133, 110976 (2021).

3.        Sidhu S. et al. Beneficial effects of Emblica officinalis in L-arginine-induced acute pancreatitis in rats. J Med Food. 2011 Jan-Feb;14(1-2):147-55. doi: 10.1089/jmf.2010.1108.

                                                   END OF THE DOCUMENT

You may like to read these links: 

1. List of All SOPs and Documents for the Microbiology Laboratory

2. List of All SOPs and Documents for In-vitro Laboratory

3. List of All SOPs and Documents for the In-vivo Laboratory.

4. List of All SOPs and Documents for Clinical Research

5. List of Instruments and Equipment Used In Laboratory Animal Facility

6. Animal  Facility Design - Small Laboratory Animals (Rat, Mice, Rabbit, Guinea Pig)

7. List of Chemicals Needed for In-vivo Laboratory

8. List of Physiological Data for Small Laboratory Animals 

9. Leading Lab-Diet Suppliers in India and Beyond

10. List of All SOPs and Documents for Animal House Facility

11. List of SOPs and Documents for Histopathology Laboratory 

SHARE

Owner

Hi. I’m Writer of Researchsop.com. ’ ’ Please share these SOPs to all concern pharma people for their development. I like to fullfill the need of curious people. These things inspire me to make things looks better.

• 
• 
• 
• 
•